Novo Nordisk partners with OpenAI

Drug discovery often starts with a basic question: which protein, pathway, or cell process should a company try to change with a medicine. Novo Nordisk said Tuesday it will use OpenAI’s tools to answer that question faster across obesity and diabetes research. (cnbc.com) Novo Nordisk announced the partnership on April 14, 2026, and said OpenAI’s systems will be used to analyze large datasets, identify drug candidates, and cut the time from research to patient use. The company also said the deal includes strict data governance and human oversight. (novonordisk.com, cnbc.com) The agreement goes beyond the lab. Reuters and Novo Nordisk said the rollout will extend to manufacturing, commercial operations, and workforce training, with deployment planned across the company by the end of 2026. (usnews.com, biospace.com) Artificial intelligence in drug research is mostly pattern-finding at scale: software scans genetic, clinical, and chemistry data for signals that a human team might miss. Pharmaceutical Technology said Novo Nordisk is pitching that approach as a way to improve target selection and pipeline decisions earlier in development. (pharmaceutical-technology.com) Novo Nordisk is making the move while defending its position in obesity and diabetes. In its 2025 annual report, the company said obesity-care sales rose 26% to 82.3 billion Danish kroner, while diabetes-care sales were 207.1 billion Danish kroner and its global diabetes value share fell 3.6 percentage points over 12 months. (annualreport.novonordisk.com) Reuters framed the timing more bluntly: Novo Nordisk has been trying to respond as Eli Lilly gains ground in the weight-loss market. Bloomberg reported that Novo Nordisk did not disclose financial terms for the OpenAI deal. (usnews.com, bloomberg.com) This is not Novo Nordisk’s first artificial intelligence tie-up. Nvidia said in June 2025 that it was working with Novo Nordisk and the Danish Centre for AI Innovation on drug-discovery use cases, adding another layer to the company’s machine-learning push. (nvidia.com) OpenAI, for its part, has been pushing further into enterprise work that depends on internal data and regulated workflows. Novo Nordisk said the point of this partnership is to help its scientists and operators move faster without removing human review from decisions that affect medicines. (biospace.com, mobihealthnews.com) The test now is whether better pattern-matching changes what reaches patients, not just how quickly teams sort through data. Novo Nordisk said the goal is new treatment options delivered faster for people living with obesity and diabetes. (novonordisk.com, cnbc.com)